Table 1.
Demographic and baseline characteristics of patients with PSC.
| Total (n = 36) | Low age acceleration (n = 18) | High age acceleration (n = 18) | p value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 47 (38–51) | 49 (42–54) | 43.5 (35–48) | 0.10 |
| European descent | 30 (83.3) | 15 (83.3) | 15 (83.3) | 0.57 |
| African American | 4 (11.1) | 2 (11.1) | 2 (11.1) | |
| Native American or Alaska native | 1 (2.8) | 1 (5.6) | 0 (0) | |
| Other race | 1 (2.8) | 0 (0) | 1 (5.6) | |
| Female | 8 (22.2) | 4 (22) | 4 (22) | 1.0 |
| BMI, kg/m2 | 24.8 (23–30) | 24.8 (23–28) | 26.3 (23–31) | 0.70 |
| IBD | 17 (47.2) | 9 (50) | 8 (44.4) | 1.0 |
| UDCA use | 24 (66.7) | 12 (66.7) | 12 (66.7) | 1.0 |
| Liver biochemistry | ||||
| ALT, U/L | 52.5 (27–107) | 29 (21–52) | 83 (56–110) | 0.013 |
| ALP, U/L | 250 (119–459) | 125.5 (92–196) | 365.5 (261–599) | 0.0008 |
| GGT, U/L | 171.5 (69–459) | 84.5 (50–162) | 373 (178–521) | 0.006 |
| Liver histology | ||||
| F0-1 fibrosis | 13 (36.1) | 11 (61.1) | 2 (11.1) | 0.006 |
| F5-6 fibrosis | 23 (63.9) | 7 (38.9) | 16 (88.9) | |
| Hepatic collagen, % | 4.5 (2–9) | 2.7 (2–6) | 8.2 (4–14) | 0.005 |
| α-SMA expression, % | 4.6 (1–12) | 1.3 (1–5) | 11.4 (4–14) | 0.003 |
| Serum markers | ||||
| ELF | 9.9 (9–11) | 9.23 (8–11) | 10.9 (10–12) | 0.024 |
| IL-8, pg/ml | 29.5 (14–69) | 15.5 (11–30) | 53 (29–134) | 0.0007 |
| Total bile acids, ng/ml | 5,409 (2,249–9,973) | 4,390 (1,494–5,409) | 9,207 (6,575–43,978) | 0.11 |
Comparisons between groups were made using Wilcoxon rank-sum tests. The chi-squared test was used to compare categorical frequencies.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; IL-8, interleukin-8; GGT, gamma-glutamyltransferase; PSC, PSC, primary sclerosing cholangitis; SMA, smooth muscle actin; UDCA, ursodeoxycholic acid.